Skip to main content

SOLENO THERAPEUTICS INC

corporate_fare Company Profile

SOLENO THERAPEUTICS INC

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SLNO - Latest Insights

SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
HSR Waiting Period Expires for Neurocrine's Acquisition of Soleno Therapeutics
Sentiment: Positive
View Wiseek Article
SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 8:53 AM EDT
Filing Type: SC 14D9
Importance Score:
10
Soleno Board Unanimously Recommends Shareholders Accept Neurocrine's $53.00/Share All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 7:36 AM EDT
Filing Type: SC TO-T
Importance Score:
10
Neurocrine Biosciences Commences Tender Offer to Acquire Soleno Therapeutics for $53.00 Per Share in Cash
Sentiment: Positive
View Wiseek Article
SLNO
Apr 07, 2026, 1:15 PM EDT
Source: Reuters
Importance Score:
7
Soleno Withdraws EU Drug Application for Vykat XR Ahead of Neurocrine Acquisition
Sentiment: Negative
View Wiseek Article
SLNO
Apr 06, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
10
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash at $53.00 Per Share
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:39 AM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Deal
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Neurocrine to Acquire Soleno Therapeutics, Bolstering Rare Disease Portfolio
Sentiment: Positive
View Wiseek Article
SLNO
Mar 16, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
7
Soleno Therapeutics Amends Bylaws, Tightening Shareholder Proposal Rules and Adding Forum Selection
Sentiment: Neutral
View Wiseek Article
SLNO
Feb 26, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
7
Soleno Therapeutics Appoints Experienced Eli Lilly Veteran Jennifer Fulk as New CFO
Sentiment: Positive
View Wiseek Article
SLNO
Feb 25, 2026, 4:34 PM EST
Filing Type: 10-K
Importance Score:
9
Soleno Therapeutics Achieves First Profitable Year with $190.4M VYKAT XR Sales and $100M Share Repurchase
Sentiment: Positive
View Wiseek Article
SLNO
Feb 25, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
Soleno Therapeutics Achieves Profitability, Reports Strong VYKAT XR Launch & $190M FY25 Revenue
Sentiment: Positive
View Wiseek Article
SLNO
Jan 23, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Soleno Therapeutics Boosts Executive Compensation and Approves New Severance Plan
Sentiment: Neutral
View Wiseek Article
SLNO
Jan 12, 2026, 8:51 AM EST
Filing Type: 8-K
Importance Score:
8
Soleno Therapeutics Reports Strong Preliminary Q4 & Full-Year 2025 Results, Achieves Profitability
Sentiment: Positive
View Wiseek Article